Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling.

Find a Clinical Research Study

161 - 166 of 166

Study of Efficacy and Safety of Tisagenlecleucel in Children and Young Adults with HR B-ALL that is end-consolidation MRD Positive (AALL1721/CASSIOPEIA)

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel (also referred to as CTL019, or Kymriah™) is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL) that remains MRD-positive after 2 cycles of chemotherapy. The study is enrolling children and young adults between the ages of 1-25 who have received induction and consolidation chemotherapy for HR B-ALL but were still found to have remaining disease (MRD). If you agree to join in this study, you will get one dose of the tisagenlecleucel cells administered by intravenous infusion and be followed for leukemia response. This study also involves blood draws and assessments. Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Cancer Immunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. Shannon Maude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.

T2017-002 TACL Ixazomib Study

CHOP and the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium is conducting a study for children and young adults 21 years old or younger who have relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. This study adds the study drug 'Ixazomib' to standard relapsed ALL chemotherapy drugs. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT03817320" or visit the TACL website at https://tacl.chla.usc.edu/Tacl/#!/Page/3. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.

Talimogene Laherparepvec in advanced non-CNS tumors

Talimogene laherparepvec is a virus-basedcancer immunotherapy that is injected directly into the cancer. Tumors to beinjected must be in soft tissue and not in bone or an internal organ. Theprimary purpose is to determine whether talimogene laherparepvec is safe toadminister directly into tumors by closely monitoring its side effects and tomonitor the effect that it has on the tumors by measuring the change in thesize of the tumor after treatment.

AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations

The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy. The 3 treatment plans we will be using include: a) therapy containing the usual/standard drugs - Control Arm or, b) therapy containing cyclophosphamide and etoposide- Experimental Arm 1 or, c) therapy containing clofarabine, cyclophosphamide and etoposide – Experimental Arm 2. 

ANBL1232 Response & Biology Risk Factors in Patients with Non-High-Risk Neuroblastoma

In this study we are using new biologic features, in addition to the standard risk factors, to help decide which subjects need treatment and what the best treatment is. (Subjects are people who agree to take part in this study.) Subjects will be put into 1 of 3 different treatment groups, labeled as Group A, B and C. The group that you are put in will determine the treatment that you get.


Pages